[go: up one dir, main page]

DE602004026781D1 - USE OF PIPAMPERONE AND A D2 RECEPTOR ANTAGONIST OR A SEROTONINE / DOPAMINE ANTAGONIST - Google Patents

USE OF PIPAMPERONE AND A D2 RECEPTOR ANTAGONIST OR A SEROTONINE / DOPAMINE ANTAGONIST

Info

Publication number
DE602004026781D1
DE602004026781D1 DE602004026781T DE602004026781T DE602004026781D1 DE 602004026781 D1 DE602004026781 D1 DE 602004026781D1 DE 602004026781 T DE602004026781 T DE 602004026781T DE 602004026781 T DE602004026781 T DE 602004026781T DE 602004026781 D1 DE602004026781 D1 DE 602004026781D1
Authority
DE
Germany
Prior art keywords
antagonist
pipamperone
serotonine
dopamine
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004026781T
Other languages
German (de)
Inventor
Erik Buntinx
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PharmaNeuroBoost NV
Original Assignee
PharmaNeuroBoost NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2451798A external-priority patent/CA2451798C/en
Priority claimed from US10/725,965 external-priority patent/US7884096B2/en
Priority claimed from EP03447279A external-priority patent/EP1547650A1/en
Priority claimed from US10/752,423 external-priority patent/US7855195B2/en
Priority claimed from EP04447066A external-priority patent/EP1576985A1/en
Priority claimed from CA 2461248 external-priority patent/CA2461248C/en
Priority claimed from US10/803,793 external-priority patent/US20050119249A1/en
Priority claimed from EP04025035A external-priority patent/EP1541197B8/en
Priority claimed from CA 2487529 external-priority patent/CA2487529A1/en
Application filed by PharmaNeuroBoost NV filed Critical PharmaNeuroBoost NV
Priority claimed from PCT/BE2004/000172 external-priority patent/WO2005053796A1/en
Publication of DE602004026781D1 publication Critical patent/DE602004026781D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004026781T 2003-12-02 2004-12-02 USE OF PIPAMPERONE AND A D2 RECEPTOR ANTAGONIST OR A SEROTONINE / DOPAMINE ANTAGONIST Expired - Lifetime DE602004026781D1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US10/725,965 US7884096B2 (en) 2003-12-02 2003-12-02 Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP03447279A EP1547650A1 (en) 2003-12-02 2003-12-02 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2451798A CA2451798C (en) 2003-12-02 2003-12-02 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
EP04447001 2004-01-05
US10/752,423 US7855195B2 (en) 2003-12-02 2004-01-06 Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP04447066A EP1576985A1 (en) 2004-03-18 2004-03-18 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA 2461248 CA2461248C (en) 2003-12-02 2004-03-18 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US10/803,793 US20050119249A1 (en) 2003-12-02 2004-03-18 Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP04025035A EP1541197B8 (en) 2003-12-02 2004-10-21 Use of pipamperone and an SNDRI, SNRI or SSRI for the treatment of mood or anxiety disorders
CA 2487529 CA2487529A1 (en) 2003-12-02 2004-11-15 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
PCT/BE2004/000172 WO2005053796A1 (en) 2003-12-02 2004-12-02 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists

Publications (1)

Publication Number Publication Date
DE602004026781D1 true DE602004026781D1 (en) 2010-06-02

Family

ID=42134278

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004026781T Expired - Lifetime DE602004026781D1 (en) 2003-12-02 2004-12-02 USE OF PIPAMPERONE AND A D2 RECEPTOR ANTAGONIST OR A SEROTONINE / DOPAMINE ANTAGONIST

Country Status (8)

Country Link
AT (1) ATE464901T1 (en)
DE (1) DE602004026781D1 (en)
DK (1) DK1708790T3 (en)
ES (1) ES2343962T3 (en)
HR (1) HRP20100376T1 (en)
PT (1) PT1708790E (en)
RS (1) RS51331B (en)
SI (1) SI1708790T1 (en)

Also Published As

Publication number Publication date
HRP20100376T1 (en) 2010-08-31
RS51331B (en) 2011-02-28
DK1708790T3 (en) 2010-06-21
SI1708790T1 (en) 2010-09-30
ATE464901T1 (en) 2010-05-15
PT1708790E (en) 2010-07-09
ES2343962T3 (en) 2010-08-13

Similar Documents

Publication Publication Date Title
DE60310592D1 (en) TAILORED SCREW SPRINGS OF VARIOUS VERSION
NO20043709L (en) New aryl and heteroaryl piperazines
NO20050429D0 (en) Substituted quinoline CCR5 receptor antagonists
DE602006010870D1 (en) PIPERIDINE DERIVATIVES SUITED AS ANTAGONISTS OF HISTAMINE H3
ATE344798T1 (en) INDOLE DERIVATIVES SUITABLE AS HISTAMINE H3 ANTAGONISTS
PL374832A1 (en) New substituted benzimidazole dosage forms and methods of their use
DE602004017608D1 (en) CGRP RECEPTOR ANTAGONISTS
ATE409700T1 (en) CANNABINOID RECEPTOR LIGANDS AND THEIR USE
ATE365719T1 (en) O-CYCLOPROPYL CARBOXANILIDES AND THEIR USE AS FUNGICIDES
DE60328087D1 (en) ARYL SUBSTITUTED PYRIMIDINE AND ITS USE
ATE376357T1 (en) QUINOLINE-; ISOQUINOLINE AND QUINAZOLINE OXYALKYLAMIDES AND THEIR USE AS FUNGICIDES
IS2847B (en) Biphenyl derivatives with beta2 adrenergic receptor antagonist and muscarinic receptor antagonist activity
CY2010010I2 (en) IL-1 RECEPTOR-BASED ANTAGONISTS AND METHODS OF MAKING AND USING THEM
DE60311379D1 (en) Body-friendly scaffold to restore ligaments or tendons
DK1951660T3 (en) Histamine 3 receptor antagonists
DE60321958D1 (en) INDAZONE DERIVATIVES AND THEIR USE AS CRF ANTAGONISTS
DE60106607D1 (en) SUBSTITUTED 1-AMINOALKYL-LACTAME AND THEIR USE AS MUSCARIN RECEPTOR ANTAGONISTS
EP1782350A4 (en) COLLECTION OF PREFERENTIAL INFORMATION
ATE438395T1 (en) PYRAZOLE DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS
ITMI20021247A1 (en) NON-PEPTID BASIC ANTAGONISTS OF BRADICHININE AND THEIR USE PHARMACEUTICAL INFORMATION
ATE384054T1 (en) SUBSTITUTED BENZOXAZINONES AND THEIR USE
DE502004011575D1 (en) Use of Dioldimerfettsäureestern
DK2336124T3 (en) Stable hydrate of a muscarinic receptor antagonist
ATE363482T1 (en) SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL)PIPERIDINE FOR USE AS MUSCARINO RECEPTOR ANTAGONISTS
DE60321129D1 (en) RECOMBINANT HERPESVIRUS OF TURKEY AND USE THEREOF

Legal Events

Date Code Title Description
8364 No opposition during term of opposition